Navigation Links
YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Date:9/4/2007

zumab at three dose levels (100mg, 200mg and 400mg weekly) with palliative radiation (30 Gy in 10 fractions). The data will be used to select the optimal effective dose for the randomized Phase II component of the study, in which Overall Survival will be the primary endpoint.

Of the six patients enrolled in the 1st cohort (100mg), four Partial Response (PR) and two Stable Disease (SD) were reported as at August 14, 2007. Median Overall Survival of the group was 41.5 weeks. All patients ultimately progressed. Two severe adverse events have been reported, neither causally attributable to nimotuzumab. A notable absence of grade III/IV rash or diarrhea in this cohort was reported.

Of the seven patients enrolled in the 2nd cohort (200mg) of the study, two PR and five SD were reported as at August 14, 2007 Median overall survival of the group has not been reached but currently exceeds 25 weeks. There has been a notable absence of grade III/IV rash or diarrhea reported in this cohort.

Enrolment is now ongoing into the third cohort, to be treated at 400 mg per dose level, and accrual is anticipated to be completed by the end of 2007.

YM is conducting the trial in Canada and Kuhnil Pharmaceutical Co. is conducting a parallel trial in Korea with a common protocol. This structure is designed to accelerate overall recruitment and lower the costs to the participants. The interim report from Phase I Korean patients is anticipated early in 2008.

The poster presentation is entitled "Preliminary Results Of An Escalating Dose (Phase I /II Clinical) Trial Of The Anti EGFR Monoclonal Antibody Nimotuzumab In Combination With External Radiotherapy In Patients Diagnosed With Stage IIB, III or IV NSCLC Unsuitable For Radical Therapy" by Gwyn Bebb, Colum Smith, Anthony Brade, Stewart Rorke and Igor Sherman. The poster, P3 - 023, will be on display on September 5 & 6 at Atlantic Halls 5 - 8 in poster session 3 - Novel Therapeutics: Molecular Therapeutics.


'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 29, 2014 Global polyvinyl chloride ... world economic crisis during 2008-2009, especially in North America ... and currently is keeping to a growing trend. , ... is utilized in the construction segment. In 2013, the ... profiles, tubing, sheets and rigid film. Moreover, the PVC ...
(Date:10/30/2014)... 30, 2014 Rancho BioSciences , ... have manually curated public data source TCGA ... the data is now available for other oncology ... public and internal data sources for their Pharma, Government ... of the data that becomes more easily accessible. ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success ... of its fleet of high volume High Pressure Processing (HPP) ... we return to PackExpo this year, which is where we ... said Jeff Williams, CEO at Avure. “Sales of the new ... be meeting the challenges of market demand for higher throughput. ...
(Date:10/30/2014)... N.J. , Oct. 30, 2014  Regado Biosciences, ... it will hold a conference call and live audio ... EST to discuss its third quarter 2014 financial results. ... conference call by dialing (888) 347-1165 for domestic callers ... will be webcast live under the investor relations section ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... LA JOLLA, Calif., Oct. 29 Immunosyn,Corporation (OTC ... G.,David Criner as the company,s Chief Financial and ... Douglas A.,McCain, Jr., has been appointed as the ... position as Corporate Secretary. "I believe that ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
... Ltd., the Innovator in,Ultrasound for more than 50 years, ... platforms for advanced cardiac and,vascular imaging, the ProSound Alpha ... of American Heart Association, at the Orange County,Convention Center ... Alpha 7 and the Alpha 10 incorporate all of ...
Cached Biology Technology:Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 3
(Date:10/29/2014)... living world compete with members of their own ... they invest into their competitive ability. Some individuals ... to high-quality resources, while others seem to avoid ... resources that are left over for them. Moreover, ... societies seems to fluctuate considerably over time. A ...
(Date:10/29/2014)... kidney cancer patients in Europe sheds light on the ... apparent link between exposure to aristolochic acid and incidence ... by an international team led by scientists from the ... underscores the importance of investigating possible sources of exposure ... the Aristolochia genus, also has been suspected of causing ...
(Date:10/28/2014)... have published a paper in the Proceedings of ... details about key transitions in the evolution of plant ... mosses, ferns, trees and flowers growing deep in steamy ... the ornamental plants adorning our homes, all plant life ... "Our study generated DNA sequences from a vast number ...
Breaking Biology News(10 mins):Evolution of competitiveness 2Evolution of competitiveness 3Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3
... The Aplastic Anemia & MDS International Foundation (AA&MDSIF) ... & Drug Administration (FDA) has expanded the label for ... which found that Vidaza is the only agent that ... also shown to delay progression to acute myelogenous leukemia ...
... in German . , Bremerhaven, August 19th ... Wegener Institute for Polar and Marine Research in the ... time. Polarstern left the port of Reykjavik on August ... is located right in the Northwest Passage. Its destination ...
... 21, 2008) The leading figures in ... exciting breakthroughs in this revolutionary field of research at ... Translational Stem Cell Research Conference, October 14-15 at The ... on the dramatic advancements researchers are making in developing ...
Cached Biology News:RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference 2New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference 3
See product name for description....
... 20 Amino Acid length max , MS-spec check ... customer for future usage conjugation of peptide to KLH protein , ... days/each , Pre-immune bleed x1 /each ... Test bleed (app. 5 ml) x1 /each , ...
... following: , Coated Capture Antibody: 12 x 8-well ... 300 mL of 2X concentrate , Beta ... peptide , Lyophilized Standard Diluent: 3 mL , ... Secondary Antibody-HRP: 30 microL of concentrate , OPD ...
Human Cell Line Slides...
Biology Products: